Relapse drug-resistant gastrointestinal tumor Decitabine comprehensive treatment scheme

A technology of digestive tract tumor and decitabine, which is applied in the field of combination of decitabine for recurrent drug-resistant digestive tract tumor, and can solve the problems of strong cytotoxicity, bone marrow transplantation, delayed dose dependence, etc.

Inactive Publication Date: 2017-02-22
GENERAL HOSPITAL OF PLA
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, this high dose shows strong cytotoxicity and bone marrow tra

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0127] Embodiment 1 Effect of Chemotherapy Scheme for Esophageal Cancer

[0128] Intravenous infusion of decitabine (7mg / m2) on days 1-5 2 / d),

[0129] Chemotherapy is given on the 6th and 7th days; 28 days are a cycle, at least 4 cycles of treatment or continuous treatment until the disease progresses or the treatment is stopped due to intolerable side effects;

[0130] According to the RECIST (Response Evaluation Criteria in Solid Tumors) standard, imaging examinations can measure lesions, which are divided into the following indicators: (1) complete response (CR, complete response): all target lesions disappear, no new lesions appear, and Tumor markers are normal and should be maintained for at least 4 weeks; (2) partial response (PR, partial response): the sum of the maximum diameters of target lesions is reduced by ≥ 30%, and should be maintained for at least 4 weeks; (3) stable disease (SD, stable disease): The sum of the maximum diameters of target lesions shrinks bu...

Embodiment 2

[0158] The effect of embodiment 2 gastric cancer chemotherapeutic scheme

[0159] Intravenous infusion of decitabine (7mg / m2) on days 1-5 2 / d),

[0160] Chemotherapy is given on the 6th and 7th days; 28 days are a cycle, at least 4 cycles of treatment or continuous treatment until the disease progresses or the treatment is stopped due to intolerable side effects;

[0161] The chemotherapy regimen for gastric cancer is any of the following chemotherapy regimens

[0162] Gastric cancer chemotherapy regimen one,

[0163] Drug dosage (mg / m 2 ) time (days) and cycle

[0164] Cisplatin 60-75mg / m 2 IV 2, q28d

[0165] Irinotecan 140-200mg / m 2 IV 2, q28d

[0166] Enrolled cases: 7 cases

[0167] Efficacy: 2 cases obtained partial remission (PR), 5 cases had stable disease (SD);

[0168] Gastric cancer chemotherapy regimen II,

[0169] Drug dosage (mg / m 2 ) time (days) and cycle

[0170] Oxaliplatin 120-135mg / m 2 IV 1, q28d

[0171] 5-Fu 2000-2500mg / m 2 IV infusion ove...

Embodiment 3

[0183] Example 3 Effect of decitabine comprehensive treatment of recurrent and progressive gastrointestinal tumors

[0184] A total of 50 cases of recurrent and progressive gastrointestinal tumors were enrolled in the group, and were treated with decitabine comprehensive regimen. Transient lymphopenia, anemia and other blood system reactions occurred in 32% of patients, which could be relieved without intervention; the overall disease control rate was 80.77%; the best median progression-free survival (PFS) of patients before chemotherapy resistance was 6 months The median PFS was 5 months, and the overall survival (OS) was up to 18.3 months.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicines and particularly relates to a relapse drug-resistant gastrointestinal tumor Decitabine comprehensive treatment scheme and a composition of relapse drug-resistant gastrointestinal tumor Decitabine.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a decitabine comprehensive treatment scheme for recurrent drug-resistant digestive tract tumors and a combination of decitabine for recurrent drug-resistant digestive tract tumors. Background technique [0002] Traditional treatments, including chemotherapy, radiotherapy, and surgery, have achieved certain curative effects in a variety of solid tumors and hematological tumors, but most patients eventually develop resistance to these therapies, and more than 90% of tumor patients died of recurrent and metastatic disease . Considering the shortcomings of traditional therapies in the treatment of relapsed and refractory solid tumors, new therapies are urgently needed to change this situation. [0003] The occurrence and development of gastrointestinal tumors is a multi-step, multi-stage and orderly process, which is the result of the interaction between genetic factors and epigenetics, mai...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/706A61K33/24A61K31/555A61K31/519A61P35/00A23L33/00A61K31/337A61K31/4745A61K31/7068A61K31/505
CPCA61K31/706A23V2002/00A61K31/337A61K31/4745A61K31/505A61K31/519A61K31/555A61K31/7068A61K33/24
Inventor 梅倩陈美霞韩为东李祥张燕
Owner GENERAL HOSPITAL OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap